SCHEMBL2962222

SCHEMBL2962222

Nc1ncnc2c1c(-c1ccc3c(ccn3Cc3ccccc3Cl)c1)nn2C1CCC(O)CC1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 16/20 0.56
▸ PIK3CD O00329 15/20 0.56
▸ PIK3CA P42336 14/20 0.56
▸ PIK3CB P42338 14/20 0.56
▸ PIK3CG P48736 14/20 0.56
▸ PRKDC P78527 14/20 0.56
▸ ABL1 P00519 13/20 0.56
▸ HCK P08631 13/20 0.56
▸ SRC P12931 13/20 0.56
▸ KDR P35968 13/20 0.56
▸ MTOR P42345 13/20 0.56
▸ EPHB4 P54760 13/20 0.56
▸ PI4KB Q9UBF8 8/20 0.51
▸ IGF1R P08069 3/20 0.51
▸ ERBB2 P04626 2/20 0.51
▸ BTK Q06187 2/20 0.49
▸ ATR Q13535 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2960030 0.91 IGF1R (0.57) EGFRPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2953587 0.91 SRC (0.57) EGFRPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2959431 0.91 EGFR (0.56) EGFRPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2961978 0.90 SRC (0.59) EGFRPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2956132 0.89 IGF1R (0.54) EGFRPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2956130 0.89 IGF1R (0.54) EGFRPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2959607 0.89 IGF1R (0.54) EGFRPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2953983 0.89 IGF1R (0.66) EGFRKDRIGF1RERBB2
SCHEMBL2953982 0.89 IGF1R (0.66) EGFRKDRIGF1RERBB2
SCHEMBL2958145 0.88 IGF1R (0.53) EGFRPIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP claimed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US claimed
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP disclosed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US disclosed
EP-1973917-A2 PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2008-10-01 — — EP disclosed
US-20070203143-A1 PROTEIN KINASE INHIBITORS ABBVIE INC. 2007-08-30 — — US disclosed
WO-2007079164-A2 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203143-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 EGFR 591/4885PIK3CD 264/4885PIK3CA 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback